Biomarker Discovery Outsourcing Services Market Size Worth $70.44 Billion By 2032 | CAGR: 20.8%

The global biomarker discovery outsourcing services market size is expected to reach USD 70.44 billion by 2032, according to a new study by Polaris Market Research. The report “Biomarker Discovery Outsourcing Services Market Share, Size, Trends, Industry Analysis Report, By Type; By Therapeutic Area (Oncology, Neurology, Cardiology, Autoimmune Diseases, Others); By Discovery Phase; By End-use; By Region, And Segment Forecasts, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Rising use of biomarkers in clinical trials, leading to an increased demand for outsourced biomarker research services by pharmaceutical companies. Additionally, the pharmaceutical industry is increasingly outsourcing various aspects of its operations, including biomarker research, contributing to the market's expansion. Another driving force is the growing adoption of liquid biopsies, a technique that involves analyzing biomarkers in bodily fluids like blood, urine, and cerebrospinal fluid. Liquid biopsies offer advantages over traditional tissue biopsies, being less invasive and providing real-time information. As the popularity of liquid biopsies rises, the demand for biomarker discovery outsourcing services is also increasing, making it a pivotal factor in the market's growth.

The market is experiencing significant growth due to the rise in drug development and clinical trials. Biomarkers have become pivotal in drug development, aiding pharmaceutical companies in pinpointing appropriate drug targets, streamlining clinical trial procedures, and identifying suitable patient populations for trials. As of 2023, the global clinical trial landscape boasts an impressive 452,604 registered trials on ClinicalTrials.gov, with 64,838 actively enrolling participants. This marks a substantial increase compared to the approximately 365,000 registered trials noted in early 2021, highlighting the robust and continuous expansion within the realm of clinical research.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/biomarker-discovery-outsourcing-services-market/request-for-sample

The future of biomarker discovery is heavily reliant on advancements in omics technologies. Genomics, proteomics, metabolomics, and other omics disciplines have made significant progress, allowing scientists to identify new biomarkers. Integrating data from these various omics fields is incredibly beneficial for biomarker identification. By combining insights from genomics, proteomics, and metabolomics, researchers can gain a comprehensive understanding of complex disorders.

Outsourcing services that specialize in multi-omics data integration play a crucial role in this process. These specialized service providers have the expertise to navigate the complexities of different omics data and integrate them effectively. By outsourcing biomarker discovery efforts to these experts, pharmaceutical companies and research institutions can leverage the latest technologies and methodologies, leading to the identification of innovative biomarkers essential for advancing diagnostics and therapeutics in the field of healthcare.

Biomarker Discovery and Outsourcing Services Market Report Highlights

• Surrogate endpoints dominated the market, as they precise drug’s mechanism of action, paving the way for personalized therapies.
• The oncology segment held the largest share, owing to rising cases of cancer and investments in cancer research
• North America dominated the market, as it possesses a huge industry-academia network, the presence of research funding, and key companies involved in computational biology
• The key market players include Laboratory Corporation of America, Charles River Laboratories, Eurofins Scientific, Celerion, ICON, Parexel, and Proteome Sciences

Polaris Market Research has segmented the biomarker discovery and outsourcing services market report based on type, therapeutic area, discovery phase, end use, and region:

Biomarker Discovery and Outsourcing Services, Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Predictive biomarkers
• Prognostic biomarkers
• Safety biomarkers
• Surrogate endpoints

Biomarker Discovery and Outsourcing Services, Therapeutic Area Outlook (Revenue - USD Billion, 2019 - 2032)

• Oncology
• Neurology
• Cardiology
• Autoimmune Diseases
• Others

Biomarker Discovery and Outsourcing Services, Discovery Phase Outlook (Revenue - USD Billion, 2019 - 2032)

• Biomarker Identification
• Biomarker Validation
• Biomarker Profiling
• Biomarker Panel Development
• Biomarker Selection

Biomarker Discovery and Outsourcing Services, End Use Outlook (Revenue - USD Billion, 2019 - 2032)

• Pharmaceutical Companies
• Biotechnology Companies
• Others

Biomarker Discovery and Outsourcing Services, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia

• Latin America

• Argentina
• Brazil
• Mexico

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa

Biomarker Discovery Outsourcing Services Market Report Scope